Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Revelation Biosciences Inc (REVBW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: REVBW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -87.5% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 19094 | Beta 0.18 | 52 Weeks Range 0.00 - 0.03 | Updated Date 03/29/2025 |
52 Weeks Range 0.00 - 0.03 | Updated Date 03/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.93% | Return on Equity (TTM) -264.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 859179 |
Shares Outstanding - | Shares Floating 859179 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Revelation Biosciences Inc
Company Overview
History and Background
Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of immunomodulatory therapies to prevent and treat disease. Founded to exploit the innate immune system, Revelation Bio is still in its early growth stage.
Core Business Areas
- REVTx-99: Antiviral immunomodulator focusing on influenza A (including potential pandemic strains) and influenza B viral infections. Aims to enhance the immune response to these viruses.
- REVTx-300: Immunomodulator being investigated for the treatment of chronic organ inflammation, with an initial focus on inflammatory bowel disease (IBD). Intended to modulate the immune system to reduce inflammation.
- REVDx-501: A rapid nasal swab diagnostic test to detect all upper respiratory viral infections, intended for point-of-care use.
Leadership and Structure
James Rolke is the Chief Executive Officer. The company has a Board of Directors that provides strategic oversight. It operates with functional teams for R&D, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- REVTx-99: REVTx-99 is their lead drug candidate currently in clinical trials for the treatment of influenza infections. Market share data is not yet available as it is still in development. Competitors include companies developing antiviral drugs, such as Roche (Tamiflu) and Gilead Sciences (Tamiflu, Xofluza).
- REVTx-300: REVTx-300 is in development for IBD treatment. No market share as it is not approved. Competitors are numerous and well established including Janssen (Stelara), AbbVie (Humira & Rinvoq), Takeda (Entyvio).
- REVDx-501: REVDx-501 is a diagnostic product in development. Market share is unavailable. Competitors include Abbott (BinaxNOW), Quidel (Sofia), and Roche diagnostics.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The demand for innovative therapies and diagnostics for infectious diseases and inflammatory conditions is significant.
Positioning
Revelation Biosciences is positioned as an innovative biopharmaceutical company focused on leveraging the innate immune system. Its competitive advantage lies in its proprietary technology platform and potential to develop novel therapies for unmet medical needs.
Total Addressable Market (TAM)
The TAM for influenza therapies and IBD treatments is substantial, estimated to be billions of dollars globally. Diagnostic testing for respiratory viruses also represents a significant market opportunity. Revelation is attempting to disrupt established treatment paradigms within these large TAMs with innovative immunomodulatory approaches.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform targeting the innate immune system
- Potential for first-in-class immunomodulatory therapies
- Experienced management team
- Clinical-stage assets with promising preclinical and early clinical data
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
- Single product pipeline with high risk
- Lack of commercial infrastructure
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion of the product pipeline through additional indications or new targets
- Positive clinical trial results leading to regulatory approval
- Government funding and grants for infectious disease research
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Patent challenges and intellectual property disputes
- Market access and reimbursement challenges
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Gilead Sciences (GILD)
- Johnson & Johnson (JNJ)
- Abbott (ABT)
- QuidelOrtho (QDEL)
Competitive Landscape
Revelation Biosciences faces intense competition from established pharmaceutical and diagnostics companies. Its success will depend on demonstrating superior efficacy and safety compared to existing treatments and securing strategic partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its product candidates through preclinical and early clinical development.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization partnerships. Analyst estimates are likely to be highly speculative at this stage.
Recent Initiatives: Recent initiatives include advancing REVTx-99 into Phase 2 clinical trials and progressing the development of REVDx-501.
Summary
Revelation Biosciences is a high-risk, high-reward clinical-stage company. Its strength lies in its innovative technology platform and potential for first-in-class therapies. However, it faces significant challenges related to funding, clinical trial success, and competition from larger companies. The company needs to carefully manage its cash runway and achieve key milestones to attract further investment and strategic partnerships.
Similar Companies
BNTX
BioNTech SE
BNTX
BioNTech SE
MRNA
Moderna Inc
MRNA
Moderna Inc
VIR
Vir Biotechnology Inc
VIR
Vir Biotechnology Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (where available)
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revelation Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-16 | CEO & Director Mr. James M. Rolke | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.revbiosciences.com |
Full time employees 8 | Website https://www.revbiosciences.com | ||
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.